71 results about "Type Vaccine" patented technology

The invention discloses an ultralow-viscosity water-in-oil vaccine adjuvant and a preparation method thereof, and the ultralow-viscosity water-in-oil vaccine adjuvant comprises the following components in percentage by weight: 73%-75% of oil for injection, 20%-23% of a compound emulsifier, 2%-7% of a stabilizer, 0.5%-1.5% of a chiral immunomodulator and 1%-2% of a temperature-responsive material, the preparation method comprises the following steps: heating oil for injection as an oil phase; adding the compound emulsifier, the stabilizer, the chiral immunomodulator and the temperature response type material into the oil phase, stirring until the materials are completely dissolved to form a uniform oil phase mixture, slowly adding the water phase into the oil phase mixture, performing high-speed shearing to form primary emulsion, homogenizing the primary emulsion, and performing freeze drying to obtain the chiral immunomodulator. And carrying out emulsion refining by adopting a micro-fluidic technology to obtain the ultralow-viscosity water-in-oil type vaccine adjuvant. The ultra-low viscosity and injection comfort are achieved, precise immunization is achieved for different pathogens, multiple immune pathways are activated at the same time, a wide and lasting protection effect is generated by training an immune mechanism, and the ultra-low viscosity and injection comfort have the intelligent drug release characteristic, excellent stability and broad-spectrum applicability.

The invention relates to a method for detecting the in vitro relative potency of a type 9 HPV vaccine or antigen stock solution. Specifically, the in vitro relative potency of an HPV-VLP antigen stock solution and vaccine finished products (types 6, 11, 16, 18, 31, 33, 45, 52 and 58) is detected by using an enzyme-linked immunosorbent assay. The enzyme-linked immunosorbent assay has excellent accuracy and precision, the standardization level of HPV vaccine quality evaluation is improved, and a foundation is expected to be laid for promoting research and development of high-quality HPV vaccines.

The invention discloses an antigen LARP1 of cysticercus bovis and application of the antigen LARP1, and belongs to the technical field of biochemistry. The invention aims to provide a detection method and a treatment and prevention method for cysticercosis bovis. The invention provides an antigen of cysticercus bovis. The amino acid sequence of the antigen of cysticercus bovis is as shown in SEQ ID NO. 4. And a new candidate antigen is provided for research and development of novel vaccines, development of specific diagnostic reagents and the like.

This invention belongs to the field of biotechnology and relates to a specific monoclonal antibody against porcine circovirus type 2 (PCV2) Cap protein and its applications. The CDR of the heavy chain variable region of the monoclonal antibody includes CDR1, CDR2, and CDR3 as shown in SEQ ID No. 1, SEQ ID No. 2, and SEQ ID No. 3, respectively; the CDR of the light chain variable region of the monoclonal antibody includes CDR1, CDR2, and CDR3 as shown in SEQ ID No. 4, SEQ ID No. 5, and SEQ ID No. 6, respectively. A sandwich ELISA method for protein content determination has been established, which is simple to operate, has good sensitivity and specificity, is widely applicable, and can perform high-throughput determination of multiple samples to detect the content of Cap protein, an effective antigen of various types of PCV2 vaccines, thus shortening the vaccine testing time.

The invention provides a novel vaccine adjuvant and application of the novel vaccine adjuvant in preparation of the vaccine adjuvant. The BCG-PSN and vaccine induced RBD specific IgG antibody and neutralizing antibody level are equivalent to those of an aluminum adjuvant, the BCG-PSN and vaccine induce Th1 biased T cell reaction, the induced T cell response level is obviously higher than that of the aluminum adjuvant, and K18-hACE2 mice are protected from being affected by Delta variant induced lung lesions. As a vaccine adjuvant, BCG-PSN has wide compatibility and safety, and has no toxic or side effect.

The application discloses a Mycoplasma bovum adhesion protein FtsZ and application thereof. The nucleic acid sequence of the Mycoplasma bovum adhesion protein FtsZ is shown as SEQ ID NO. 1. The application also discloses a recombinant plasmid pET-30a-ftsZ and an E. coli containing the recombinant plasmid pET-30a-ftsZ. ftsZ The recombinant protein rFtsZ has the advantages of being capable of specifically combining with EBL cell membrane protein, being capable of combining with extracellular matrix components (fibronectin, fibronectin, laminin and type IV collagen), having the direct adhesion host cell effect, having good antigenicity, being capable of producing high-level antibodies, being capable of providing good immune protection effect, and providing a new target and thought for elucidating the pathogenic mechanism of the Mycoplasma bovum and developing a new vaccine and medicine.

Described herein are novel vaccine compositions and methods for use thereof in inducing an immune response in a subject especially aged subjects. Specifically exemplified are vaccine compositions that include an antigen; a cyclic dinucleotide; soluble tumor necrosis factor (TNF); or a CD64 antibody or antibody fragment. Optionally, the vaccine composition comprises a TNF conjugated with a moDC targeting moiety in addition to or in place of TNF or CD64 antibody or antibody fragment, or both TNF and CD64 antibody or antibody fragment.

The application discloses a temperature-uniform vaccine rewarming device, which belongs to the technical field of vaccine rewarming devices. The device comprises a shell, an electric heating wire arranged in the shell, a sealing cover threadedly connected to the upper side of the shell, a support disc sealingly and slidably connected to the shell, a water bath cavity formed by the shell and the support disc, water bath liquid stored in the water bath cavity, a support ring annularly arranged on the support disc, symmetrical connecting rods fixed to the lower side of the support ring, and an extrusion disc jointly and limitingly connected to the connecting rods symmetrically arranged on the same support ring. The connecting rod on one side is sealingly and slidably connected to a first extrusion cylinder fixed to the adjacent extrusion disc, and an annular air bag is fixed to the support ring. The annular air bag is inflated to separate the water bath liquid from the bottleneck of the vaccine, so that the water bath liquid is prevented from splashing into the bottle mouth of the vaccine during movement, and the probability of the vaccine being contaminated is reduced.

This invention belongs to the field of biomedical technology, specifically relating to a method for constructing a highly cell-adaptive PEDV GIIc recombinant chimeric virus. Specifically, this invention, based on the PEDV viral S protein determining PEDV's cell adaptability, innovatively elucidates that S2 is the key subunit determining its cell adaptability. On this basis, this invention proposes a scheme that can increase viral titer and thus reduce vaccine production costs when preparing candidate vaccine strains of circulating PEDV strains (especially GIIc). This involves retaining the S2 subunit of the highly cell-adaptive strain and replacing the S1 subunit of the highly cell-adaptive strain with the S1 subunit of the circulating strain, or replacing the S2 subunit of the circulating strain with the S2 subunit of the highly cell-adaptive strain. This scheme can both preserve the immunogenicity of the circulating strain and improve the efficiency of high-titer vaccine production.

The invention relates to the technical field of mRNA vaccine preparation, and particularly discloses a porcine epidemic diarrhea virus mRNA vaccine and a preparation method thereof. The mRNA vaccine is prepared by adopting cow milk source exosome as a carrier and wrapping mRNA encoding PEDV-S protein in the carrier through an ultrasonic loading method. According to the preparation method, the encapsulation efficiency of mRNA and the stability of the vaccine are remarkably improved, the prepared vaccine can more efficiently promote antigen expression, stronger cellular immunity and humoral immunity are induced in a mouse body, and a safe and efficient novel vaccine candidate is provided for preventing and controlling porcine epidemic diarrhea.

The invention discloses a cGAS-STING pathway activated tumor vaccine based on X-type framework nucleic acid, and belongs to the technical field of biological medicine and immune engineering. The vaccine is composed of X-type framework nucleic acid and alkynyl modified antigen peptide, the X-type framework nucleic acid is of a four-arm Halide knot structure formed by self-assembly of four oligonucleotide chains, and the antigen peptide is coupled to the oligonucleotide chains. According to the invention, the unique multi-branch topological structure of the X-type framework nucleic acid is utilized to enhance the binding stability with cGAS and efficiently activate a cGAS-STING signal channel without additional adjuvants; meanwhile, stable presentation and efficient delivery of the antigen peptide are realized, dendritic cell maturation and antigen presentation are promoted, and strong antigen specific CD8 + T cell immune response is induced. The vaccine shows a remarkable tumor inhibition effect in tumor prevention and treatment models, has the advantages of stable structure, high immunization efficiency, good safety and the like, and provides a novel vaccine platform for tumor immunotherapy.

The utility model relates to the technical field of vaccine bottle drying devices, in particular to a multi-station cooperative type vaccine bottle surface quick drying device which comprises a rack, a stock bin and a sorting bin, a vibration mechanism is further arranged on the rack, and the stock bin and the sorting bin are located above the vibration mechanism. A discharging channel extending outwards is arranged on the side, close to the feeding end of the sequencing bin, of the stock bin, and a plurality of flow guide grooves are formed in a bottom plate of the sequencing bin. A blow-drying machine is further arranged above the stock bin, an air outlet of the blow-drying machine faces the stock bin, and air flows from the stock bin to the sorting bin through the discharging channel. According to the utility model, the blow-drying machine blows a large area of air above the stock bin, so that a plurality of vaccine bottles are primarily blown; under the action of continuous vibration and stirring of the vaccine bottles, air can make contact with all faces of the vaccine bottles, and the air enters the sorting bin under the guidance of the discharging channel to conduct secondary blowing on the vaccine bottles arranged in the flow guide groove in order; no extra workload needs to be added in the whole process, and the production efficiency is greatly improved.

An adjuvant polypeptide, a nano-carrier and application of the nano-carrier in vaccine adjuvant, the present application relates to the field of vaccine.The present application solves the problems of poor antigen compatibility, lack of targeting, low delivery efficiency and insufficient preparation stability of traditional adjuvant.The amino acid sequence of the adjuvant polypeptide Adp is VLGKLAKVAI.The nano-carrier is prepared from the adjuvant polypeptide and antigen.The nano-carrier is prepared by mixing the adjuvant polypeptide and antigen through in-situ radical polymerization.The application of the nano-carrier in vaccine adjuvant.The present application screens a new vaccine adjuvant by bioinformatics method, so that it has the abilities of dendritic cell targeting and intracellular STING pathway activation, thereby enhancing the cross-presentation of antigen.Based on this, the new adjuvant is coupled with monomer, and an intelligent vaccine delivery system is constructed by in-situ polymerization method, so as to realize the efficient delivery of tumor cell membrane protein antigen and improve the immunotherapy effect of tumor vaccine.

This invention provides a virus-like particle vaccine gE-eVLP for varicella-zoster virus, a recombinant adenovirus vector vaccine, an mRNA vaccine, and their preparation methods and applications, belonging to the field of vaccine technology. The nucleotide sequence of the virus-like particle vaccine gE-eVLP provided by this invention includes a signal peptide sequence, a truncated and / or mutated sequence of the gE domain without the original signal peptide, and an EGE motif; the recombinant adenovirus vector vaccine and mRNA vaccine contain gE-eVLP. This invention innovatively integrates EABR self-assembled particle technology into the VZV adenovirus vector vaccine and mRNA vaccine technology platform, and systematically evaluates the immunogenicity of three novel vaccines: Ad26-tPA-gE-eVLP, AdC68-tPA-gE-eVLP, and LNP-tPA-gE-eVLP, providing important experimental evidence for the development of a new generation of highly effective and safe VZV vaccines.

The present application relates to a method for detecting the in vitro relative potency of HPV-9 vaccine or antigen stock solution, and specifically applying enzyme-linked immunoassay to detect the in vitro relative potency of HPV-VLP antigen stock solution and vaccine finished product (types 6, 11, 16, 18, 31, 33, 45, 52 and 58). The enzyme-linked immunoassay of the present application has excellent accuracy and precision, improves the standardization level of HPV vaccine quality evaluation, and is expected to lay a foundation for promoting the research and development of high-quality HPV vaccine.

The invention discloses an influenza B virus T3 peptide fragment capable of inducing cellular immune response and application of the influenza B virus T3 peptide fragment, and belongs to the technical field of immunotherapy and immunodetection. According to the invention, detection is carried out through ELISpot, and the immunogenicity of the long peptide (SEQ ID NO.1, named as T3) is verified in 21 volunteers. The result shows that the T3 is detected to be positive in four persons, and the positive rate is 19.05%; the IFN-gamma secretory cells of the human PBMCs are detected through ELISpot, and the immune response induced by the T3 in people can reach up to 2870 SFC / 106 PBMC. Therefore, the polypeptide has good immunogenicity and crowd universality, can be used as a specific detection peptide for monitoring the cellular immune level, can effectively activate the T cell immune response of the crowd, and has the potential of being used as a candidate vaccine epitope peptide to be applied to novel vaccine design.

The invention provides an anthrax-plague bivalent vaccine based on a protein cage-mRNA (messenger ribonucleic acid) technology as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the invention, the colletotrichum plague bivalent vaccine is developed by using a protein cage mRNA technology for the first time, safe and powerful multivalent immune protection is creatively realized, and the vaccine adopts four antigens F1, V, LFD1 and PAD4 subjected to attenuated variants; and by combining the advantages of no infection and no genome integration of the mRNA technology, the safety of the vaccine is remarkably improved. Prevention of bacillus anthracis and yersinia pestis is integrated into a single vaccine for the first time, an anthrax and plague bivalent vaccine platform based on a protein cage-mRNA technology is constructed, development of novel vaccines which are safe, powerful and easy to produce on a large scale is finally achieved, a key technical breakthrough is provided for prevention of fulminant infectious diseases, and the application is wide in application prospect. A new generation of anthrax plague bivalent vaccine which is safe, efficient, convenient to produce and stable in quality control is created.

The invention discloses a composite milk adjuvant, a preparation method and application of the composite milk adjuvant in vaccines, and belongs to the technical field of medicines. The technical problems to be solved are relatively weak cell immunocompetence, relatively poor immunogenicity and relatively weak immunoregulation capability. According to the technical scheme, squalene, polyoxyethylated castor oil 35 and poloxamer 407 are used as raw materials to prepare a basic formula of the milk adjuvant, an immunologic stimulant is added on the basis to prepare the composite milk adjuvant, and the physicochemical properties and safety of the composite milk adjuvant are represented. The synergistic effect of the milk adjuvant on humoral immunity and cellular immunity is further evaluated by being matched with a recombinant tuberculosis antigen Ag85B to immunize mice, and data support is provided for application of the milk adjuvant in development of novel vaccines such as tuberculosis vaccines and the like. The composite milk adjuvant prepared by the invention not only keeps good humoral immunity and induces generation of high-level IgG1 and IgG2a, but also remarkably improves the response level of cellular immunity.

The application discloses albumin site-directed modification lipid nanoparticles and preparation and application thereof, and relates to a kind of albumin site-directed modification lipid nanoparticles, which is prepared by synthesizing functionalized low molecular weight polyethylene glycol (PEG) lipid compound-maleimide derivative, together with the nucleic acid delivery lipid composition material usually used, to prepare nucleic acid-loaded lipid nanoparticles, then make the maleimide on its surface couple with the thiol group of albumin, to prepare the lipid nanoparticles with albumin site-directed modification on the surface.The application reduces the immunogenicity generated by the existing mRNA-loaded lipid nanoparticles outer layer covered PEG to the body, improves the related immune organ targeting of the nanoparticles, effectively delivers mRNA to lymph nodes to induce anti-tumor effect, and lays a foundation for further developing it as a new type of vaccine that can activate the immune system to produce anti-tumor effect.

This invention discloses a cPGES protein based on immunological screening of a bovine cysticercosis cDNA prokaryotic expression library and its applications, belonging to the field of biochemistry. The purpose of this invention is to provide a method for the detection, treatment, and prevention of bovine cysticercosis. This invention provides a bovine cysticercosis antigen, the amino acid sequence of which is shown in SEQ ID NO.4. This provides a new candidate antigen for the development of novel vaccines and specific diagnostic reagents.

Disclosed are novel vaccine compositions comprising modulated Transferrin Binding Protein B (TbpB) polypeptides or immunogenic portions thereof. Notably, the TbpB polypeptides are modulated with respect to domains known as loop domains located in the C-terminal lobe of TbpB polypeptides. The vaccine compositions may be used to ameliorate, treat or prevent pathogenic infections in humans caused by pathogenic H. influenzae strains. Related methods and uses are also disclosed.

This invention relates to the field of biomedical technology, specifically to a snake-derived nanobody against KLH and its preparation and application. The invention involves immunizing the black-browed rat snake with KLH, extracting total RNA from its splenic lymphocytes, constructing a phage display VH gene library, and, after multiple rounds of screening, obtaining nanobody sequences that specifically bind to KLH, such as KLH-1 and KLH-2. This nanobody can be efficiently and solublely expressed and purified in *E. coli*, exhibiting characteristics of small molecular weight and high affinity. This invention further provides applications for this nanobody, particularly in the preparation of KLH-targeting detection reagents or drug delivery systems. This nanobody provides a core tool molecule for developing highly sensitive KLH-targeting detection reagents, efficient drug delivery systems, and novel vaccines.

The application discloses a porcine reproductive and respiratory syndrome mutant virus and a construction method and application thereof. The application accurately analyzes key amino acid sites of PRRSV-1 determining Marc-145 cell tropism, specifically, 88(F), 94(I) and 95(L) amino acids of GP2a, 70(G), 72(N), 80(D), 154(I), 158(H) and 163(L) amino acids of GP3, and 49(D), 53(L), 54(R) and 57(G) amino acids of GP4. Three Marc-145 cell non-adapted strains are precisely point mutated, three PRRSV-1 modified strains which can adapt to Marc 145 cell in vitro passage culture are obtained, the strains can be stably passed in vitro and have good replication efficiency, and Marc-145 cells infected by the strains can produce obvious cytopathic effect, and the strains are expected to be used as a new type of PRRSV-1 vaccine.

The application belongs to the field of biology, and discloses a method for high-throughput screening of viral CTL epitopes based on immunopeptidomics, which comprises the following steps: transfecting mammalian cells with eukaryotic expression plasmids having MHC I molecules in series with the alpha chain and the beta2m chain to establish a mammalian cell line expressing animal MHC I molecules; using a virus to infect the mammalian cell line expressing MHC I molecules to prepare MHC I-peptide complexes; and obtaining antigen peptides existing in the MHC I-peptide complexes. The method takes chicken MHC I allele BF2*1901 molecules as the research object, takes H9N2 subtype avian influenza virus as the model virus, comprehensively characterizes chicken MHC I restricted H9N2 antigen peptide groups, and identifies immunodominant CTL epitope immunity, and is suitable for CTL epitope screening of different chicken MHC I molecules and different subtypes of avian influenza viruses, provides a fast, efficient and economical technical means for studying the specific binding of chicken MHC I molecules and antigen peptides, provides a favorable reference for T cell epitope screening of major animal pathogens, and provides a scientific basis for poultry disease-resistant breeding, development of new vaccines and immune evaluation strategies. Meanwhile, the application also discloses restricted epitope peptides, nucleic acid molecules and applications.

The invention relates to the technical field of viruses, in particular to a construction method and application of a porcine parvovirus full-length infectious clone carrying a stable genetic marker. The method comprises the following steps: cloning a complete genome of a porcine parvovirus SXND18 strain to a plasmid pBluescript II SK (+) through an In-fusion seamless cloning technology, so as to obtain a recombinant plasmid pSXND18; meanwhile, a new EcoRI restriction enzyme cutting site is introduced into a genome by utilizing an overlapping PCR (Polymerase Chain Reaction) technology and is used as a genetic marker for identifying a wild virus and a rescue virus; and mixing the recombinant plasmid with a transfection reagent, and transfecting ST cells to obtain the rescue virus rSXND18. The porcine parvovirus reverse genetic operating system established by the invention can be used for research in the directions of porcine parvovirus virulence analysis, cross-species transmission mechanism and the like, and also lays a foundation for research on novel vaccines of the porcine parvovirus.

This invention discloses a porcine CD40L trimer protein, a recombinant Bacillus subtilis strain expressing this protein, and its applications, belonging to the fields of microbial genetic engineering and livestock and poultry biological products technology. This invention utilizes Bacillus subtilis WB800N as a host and pHT43 as a vector to successfully construct a recombinant strain that efficiently secretes and expresses porcine CD40L trimer protein. Soluble expression of the porcine CD40L trimer protein was achieved. The amino acid sequence of the porcine CD40L trimer protein expressed by the recombinant strain is shown in SEQ ID NO:1. Immunological activity verification using this porcine CD40L trimer protein revealed that the CD40L trimer protein expressed in this invention can simultaneously activate humoral and cellular immunity, possessing practical application value as a novel vaccine adjuvant.

Provided are a Trichinella spiralis vaccine kit based on a prime-boost sequential immunization program and use thereof, improving the protective effect against trichinosis. The kit is divided into two parts; the first part is a Trichinella spiralis recombinant protein vaccine having an amino acid sequence set forth in SEQ ID NO. 1 or SEQ ID NO. 2, and the second part is a recombinant adenovirus expressing an amino acid sequence set forth in SEQ ID NO. 1. The prime-boost immunization strategy not only effectively avoids the deficiency associated with a single-type Trichinella spiralis vaccine, but also significantly improves the efficacy and durability of the immune response.

The invention provides a chicken Marek's virus (MHC) II type molecule restriction epitope peptide, a gene, a primer group, a screening method and application, and belongs to the technical field of immunology. The restrictive epitope peptide of the II-type molecule BLB2 * 21 of the chicken Marek's virus MHC is obtained through AF3 structure prediction and screening, the deviation of traditional bioinformatics prediction is avoided, and the binding activity of the epitope peptide is guaranteed through accurate structure analysis and crystallization verification; the gene for coding the chicken Marek's virus MHC II type molecule restrictive epitope peptide can be used for preparing Marek's virus epitope vaccines and T cell activators, or can be used as a detection target for evaluating the immune state of chicken flocks, and technical support is provided for Marek's disease prevention and control, disease resistance breeding and novel vaccine research and development.

The application discloses O-type foot-and-mouth disease virus polyepitope biomimetic nano self-assembly virus-like particles and a preparation method and application thereof. The O-type foot-and-mouth disease virus polyepitope biomimetic nano self-assembly virus-like particles are obtained by self-assembly of a recombinant protein SPC-B4T and 2STAP205 in vitro; wherein the recombinant protein SPC-B4T is obtained by sequentially connecting SpyCatcher, antigen epitopes of four topological representative strains of O-type and T cell epitopes of 3A in sequence; and the recombinant protein 2STAP205 is obtained by connecting genes of SpyTag to both ends of a phage AP205 gene through flexible spacers respectively. In addition, the application also prepares the virus-like particles into vaccines, and it is found that the prepared vaccines have good immunization efficacy, are a new type of vaccine with wide prospects, can provide material reserves and technical support for O-type foot-and-mouth disease prevention and control in China, and can generate great economic benefits and important social benefits.